About Eliaz Therapeutics
Mission
Our mission is to move beyond symptom management and transform the treatment of sepsis, critical illness, and other life-threatening diseases through targeted apheresis therapies designed to address underlying inflammatory and immune dysfunction.
Strategy
Eliaz Therapeutics is advancing XGAL-3® as a targeted blood purification platform for sepsis and critical care. By integrating with existing hospital apheresis infrastructure and leveraging a growing Galectin-3 focused IP portfolio, the company aims to develop scalable therapies for severe inflammatory and immune-mediated conditions.
Approach
Our approach is built on an extensive global intellectual property portfolio and years of research into the role of Galectin-3 in inflammation, fibrosis, vascular dysfunction, and organ injury. By combining targeted blood purification with existing critical care infrastructure, we aim to develop scalable therapeutic solutions for severe inflammatory conditions.
Leadership Team
Our leadership team and management support have extensive experience with startup and middle-market companies, specifically in the fields of medical devices, technology development, and biomedical science. In addition to our team members below, learn more about our scientific advisory board.
Isaac Eliaz
MD, MS, LAc
Physician and entrepreneur with 30+ years of clinical experience, Dr. Isaac Eliaz is a Gal-3 expert and inventor of the Gal-3 inhibitor. He founded Amitabha Apheresis Clinic and ecoNugenics (acquired in 2023 by a leading private equity firm). A multi-patent holder and author, Dr. Eliaz has led research in integrative medicine, developing therapies for sepsis and cancer.
Read more
Anat Stern
MSc, MBA
Business development, strategy, and operations veteran, Anat Stern has 18 years of experience in healthcare and biotechnology. She managed ecoNugenics, a nutraceutical company specializing in Galectin-3, for 7 years, leading to its successful private equity acquisition in 2023. Anat now leads ETI’s key strategic and operational efforts.
Read more
Milton Goss
BSE, MBA
Accomplished, senior accounting and financial management executive with more than 20 years of experience in the medical device, life science, and semiconductor industries. Prior to finance, worked in product development as a chemical engineer.
Read more
Dale Cumming
PhD
Dr. Cumming is a biotechnology expert with over 25 years of experience, including senior roles at Genetics Institute and GlycoDesign Inc., where he advanced therapeutics targeting cancer, inflammation, and infectious diseases. He co-founded Translational Medicines, Inc., and served as CSO for the International Consortium.
Read more
Glenn Chertow
MD, MPH
Expert in acute kidney failure and chronic kidney disease with more than 30 years of clinical experience. Dr. Chertow has conducted sponsored and NIH-funded trials throughout his career and maintained a research program devoted to improving kidney patient treatment.
Read more
Bryan Knipe
MBA
With an MBA and 20+ years of experience in financial management, business development, and M&A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, go-to-market strategies, and fostering relationships for growth.
Read more
Susan Alpert
MD, PhD
Dr. Alpert brings decades of regulatory expertise, including 13 years at the FDA, where she served as Director of the Office of Device Evaluation (1993-1999). She will guide ETI through FDA pathways, optimizing submissions and securing key regulatory approvals for XGal-3®.
Read more
Scientific Advisory Board
Our world class advisory board guides clinical and scientific development throughout the regulatory pathway.
Glenn Chertow
MD, MPH
Expert in acute kidney failure and chronic kidney disease with more than 30 years of clinical experience. Dr. Chertow has conducted sponsored and NIH-funded trials throughout his career and maintained a research program devoted to improving kidney patient treatment.
Read more
Ron Wald
MDCM, MPH, FRCPC
Nephrologist and Director of Hemodialysis at St. Michael's Hospital, Toronto, and a Professor of Medicine at the University of Toronto, focusing on critical care nephrology and maintenance dialysis. He led the STARRT-AKI trial on dialysis initiation in acute kidney injury and is part of the PHOSPHATE trial leadership.
Read more
Jeffrey L. Winters
MD
Mayo Clinic, Division of Transfusion Medicine, Professor of Laboratory Medicine & Pathology. A recognized leader in therapeutic apheresis and transfusion medicine. His clinical expertise includes apheresis, plasma exchange, hematopoietic progenitor cell collection, and blood banking. He is the former Editor-in-Chief of the Journal of Clinical Apheresis and has authored more than 150 peer-reviewed publications, helping shape global best practices in the field.
Read more
Patrick M. Moriarty
MD, FACC, FNLA
Director of the Atherosclerosis & Lipid Apheresis Center, Associate Professor of Internal Medicine, University of Kansas Medical Center.
Read more
